Compare AUPH & ALMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AUPH | ALMR |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.1B |
| IPO Year | 2014 | 2026 |
| Metric | AUPH | ALMR |
|---|---|---|
| Price | $14.88 | $28.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $18.50 | ★ $37.00 |
| AVG Volume (30 Days) | ★ 819.4K | 674.6K |
| Earning Date | 10-30-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $283,055,000.00 | N/A |
| Revenue This Year | $16.65 | $64.80 |
| Revenue Next Year | $17.73 | $37.27 |
| P/E Ratio | $19.89 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.52 | $21.58 |
| 52 Week High | $19.25 | $39.61 |
| Indicator | AUPH | ALMR |
|---|---|---|
| Relative Strength Index (RSI) | 32.23 | 45.59 |
| Support Level | $14.76 | $23.87 |
| Resistance Level | $15.15 | $29.06 |
| Average True Range (ATR) | 0.53 | 2.38 |
| MACD | -0.19 | -0.06 |
| Stochastic Oscillator | 4.44 | 47.77 |
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.